ES2659353T3 - Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer - Google Patents

Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer Download PDF

Info

Publication number
ES2659353T3
ES2659353T3 ES10825771.8T ES10825771T ES2659353T3 ES 2659353 T3 ES2659353 T3 ES 2659353T3 ES 10825771 T ES10825771 T ES 10825771T ES 2659353 T3 ES2659353 T3 ES 2659353T3
Authority
ES
Spain
Prior art keywords
food
component
meals
providing
cancer patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10825771.8T
Other languages
English (en)
Inventor
Valter D. Longo
Changhan Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2659353T3 publication Critical patent/ES2659353T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Operations Research (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un envase de comida terapéutica para su uso para proporcionar comidas a un paciente con cáncer, que retrasa el crecimiento del cáncer y mejora la eficacia de los fármacos quimioterapéuticos, comprendiendo el envase de comida terapéutica: un primer componente de comida dividido en comidas, que proporciona al paciente con cáncer como máximo el 50% de la ingesta calórica normal del paciente, proporcionando el primer componente de comida, al paciente con cáncer, de 700 a 1200 kcal/día, procediendo de la grasa al menos el 50% de las kilocalorías, proporcionando el primer componente de comida, comidas durante un primer período de tiempo predeterminado de aproximadamente 1 a 5 días; un segundo componente de comida dividido en comidas, proporcionando el primer componente de comida al paciente con cáncer, como máximo 500 kcal/día, proporcionando el segundo componente de comida, comidas durante un segundo período de tiempo predeterminado de aproximadamente 2 a 7 días; y una composición reponedora que comprende aminoácidos esenciales y otros aminoácidos no esenciales, ácidos grasos esenciales, minerales, vitaminas y/o extractos de verduras, durante un tercer período de tiempo predeterminado.
ES10825771.8T 2009-10-22 2010-10-22 Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer Active ES2659353T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US254154P 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (1)

Publication Number Publication Date
ES2659353T3 true ES2659353T3 (es) 2018-03-14

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10825771.8T Active ES2659353T3 (es) 2009-10-22 2010-10-22 Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer

Country Status (13)

Country Link
US (2) US20110118528A1 (es)
EP (1) EP2490684B1 (es)
JP (1) JP2013508411A (es)
CN (1) CN102753162A (es)
AU (2) AU2010310515B2 (es)
BR (1) BR112012009423A2 (es)
CA (1) CA2779282C (es)
DK (1) DK2490684T3 (es)
ES (1) ES2659353T3 (es)
PL (1) PL2490684T3 (es)
PT (1) PT2490684T (es)
RU (1) RU2549954C2 (es)
WO (1) WO2011050302A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
KR20180002677A (ko) * 2015-04-16 2018-01-08 유니버시티 오브 써던 캘리포니아 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
RU2018114459A (ru) * 2015-09-21 2019-10-23 Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре Новые стратегии лечения рака крови
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
US12042477B2 (en) * 2016-02-23 2024-07-23 Cancer Research Technology Limited Dietary product devoid of at least two non essential amino acids
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
WO2020015842A1 (en) * 2018-07-18 2020-01-23 Michalsen Andreas Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
WO2021118324A1 (ko) * 2019-12-13 2021-06-17 서울대학교산학협력단 암의 예방 또는 치료용 약학 조성물
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US12220402B2 (en) 2020-06-03 2025-02-11 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
TW202227113A (zh) * 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
US20240000125A1 (en) * 2020-12-17 2024-01-04 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
AU5319499A (en) * 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
EP2156188B1 (en) * 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Also Published As

Publication number Publication date
AU2010310515A1 (en) 2012-05-17
EP2490684B1 (en) 2018-01-03
JP2013508411A (ja) 2013-03-07
US20110118528A1 (en) 2011-05-19
PT2490684T (pt) 2018-04-02
US20210209516A1 (en) 2021-07-08
BR112012009423A2 (pt) 2017-06-13
RU2012118588A (ru) 2013-11-27
AU2016201607A1 (en) 2016-03-31
RU2549954C2 (ru) 2015-05-10
PL2490684T3 (pl) 2018-07-31
DK2490684T3 (en) 2018-04-09
EP2490684A4 (en) 2016-05-04
WO2011050302A3 (en) 2011-08-25
AU2016201607B2 (en) 2017-11-30
CA2779282A1 (en) 2011-04-28
WO2011050302A2 (en) 2011-04-28
AU2010310515B2 (en) 2016-01-07
CA2779282C (en) 2017-12-05
CN102753162A (zh) 2012-10-24
EP2490684A2 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
ES2659353T3 (es) Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer
Farahat et al. Effect of dietary supplementation of grape seed extract on the growth performance, lipid profile, antioxidant status and immune response of broiler chickens
ES2807781T3 (es) Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1
ES2954473T3 (es) Aditivo para alimentación de ganado
ES2571856T3 (es) Uso de composiciones nutricionales para prevenir la adiposidad visceral
CO6351747A2 (es) Composicion nutricional para promover desarrollo y crecimiento saludables
EA201270274A1 (ru) Натуральный экстракт из цельных плодов банана (musa spp.)
PH12012502279A1 (en) Tube feed formulations and methods for using same
BR112017009678A2 (pt) composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma
ES2947500T3 (es) Composiciones orales antiparasitarias
Kale et al. Role of antioxidants and nutrition in oxidative stress: A review
RU2006130739A (ru) Питательная композиция для улучшения состояния кожи и предотвращения кожных заболеваний
Owens Nutritional support to counteract muscle atrophy
CL2023002451A1 (es) Composiciones y métodos que usan una combinación de oleuropeína y vitamina b6
Sahin et al. Role of the antioxidant defence system and transcription factors in preventing heat stress in poultry: a dietary approach
Alagbe et al. Albizia lebbeck stem bark aqueous extract as alternative to antibiotic feed additives in broiler chicks diets: Haematology, Serum indices and oxidative status
Alalwan Nutraceuticals and their role in promoting musculoskeletal healthy aging.
EA202092105A1 (ru) Фармацевтический состав или состав пищевой добавки на основе альфа-лактальбумина
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
ES2716278T3 (es) Productos para administración oral que comprenden extractos de granada Punica granatum, pensados para un animal de compañía, y aplicaciones de los mismos
Sutili et al. Clove Oil, eugenol effective anesthetics for silver catfish, other Brazilian species
US10499664B2 (en) Fish feed formulation of Hypericum perforatum, Rosamarinus officianalis or a mixture thereof
RU2013154562A (ru) Способы и композиции для сохранения безжировой массы тела в процессе похудения
JP2020503061A (ja) 心血管性の効率に影響を与える栄養補助食品
RU2012156681A (ru) Средство (варианты), фармацевтическая композиция и способ химиопрофилактики предрака и рака предстательной железы